Drugs / pegylated liposomal doxorubicin (PLD)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05613088 | Feb 2023 → Jun 2024 | ovarian neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07214779 | Dec 2025 → Nov 2028 expected | ovarian cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01388621 Background | Oct 2011 → Jul 2014 | ovarian cancer | WiSP Wissenschaftlicher Service Pharma GmbH | Unknown | No outcome recorded |
| Phase 3 | NCT07604766 Comparator | Jun 2026 → Sep 2027 expected | refractory malignant neoplasm | Genmab | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated Liposomal Doxorubicin (PLD) | “pegylated liposomal doxorubicin (PLD)” NCT07214779 ↗ |
| Route | Intravenous | “IV infusion” NCT07604766 ↗ |